SARAH-JANE Dawson published a paper on the management of metastatic breast cancer in the NEJM, 13 March 2013.
The management of metastatic breast cancer requires monitoring of the tumour burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumour cells have been widely studied.
However, circulating cell-free DNA carrying tumour-specific alterations (circulating tumour DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer…Read more
Source: http://www.nejm.org
